December 18, 2025: Veeva continues to expect the vast majority of Veeva CRM customers will select Vault CRM, including about 14 of the top 20 biopharmas, and expects to retain at least 70% market share for biopharma CRM subscription revenue through 2030.CRM Suite represented about 75% of total Veeva revenue ten years ago, is about 20% today, and is expected to be about 10% by 2030 largely due to the growth across our broad-based business. Veeva continues to be on track for its $6 billion revenue run-rate goal in 2030.Forward-Looking StatementsThe statements above are based on our current expectations. Actual results could differ from our current expectations and we have no obligation to update such statements. A discussion of risks that have the potential to negatively impact our results can be found in our SEC filings.